Kymera IPO Presentation Deck

CANCER FIBROSIS Solid Tumors KYMERA Autoimmune SIROURES STAT3 Degradation as Resistant Mechanism in Solid Tumors - STAT3 is activated across a wide range of cancer cells in response to TKI's and chemotherapies, eventually leading to resistance and disease progression. . For example, when EGFR mutant (but not WT) NSCLC cell line H1650 was treated with erlotinib, upregulation of p-STAT3 was observed, which was reversed by STAT3 degrader Treatment with Erlotinib (1uM) Treatment with STAT3 Degrader (1 µM) p-STAT3 (Y705) STAT3 Actin X X X X > ✓ ✓ X X ✓ ✓

View entire presentation